Long‐term results of M‐TEER: A mountain of data with gaps to cross

Abstract

Key Points 3‐year data of the CLASP EFS trial demonstrate sustainable results of the PASCAL device with similar adverse events to previously published data. Contempoarary heart failure medical therapy should be considered and evaluated especially for the FMR population. Published guidelines and detailed echocardiographic data should be carefully examined especially as we target differentiating post M‐TEER residual MR ≤1 vs. ≤2.